Resultados da pesquisa - Portal para modelos de dados médicos (portal MDM)

Grupos de itens: Date of physical examination, Visit Week physical examination, B- Symptoms, Physical Examination, Organ/ System, Visit Week laboratory, Hematology, Chemistry

Study ID: 104507 Clinical Study ID: BEX104507 Study Title: Phase II Study of Iodine-131 Anti-B1 Antibody for Non Hodgkin’s Lymphoma Patients who have Previously Received Rituximab Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00996593 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin

Laboratory 3- Weeks Visits SirTac NCT02936388 - Laboratory 3- Weeks Visits

- 31/01/2022 - 1 Formulário, 1 Grupo de itens, 29 Elementos de dados, 1 Idioma

Grupo de itens: Laboratory

Study part: Laboratory 3- Weeks Visits. A Randomized Phase II Trial of Transarterial Radioembolisation With Yttrium-90 (SIRT) in Comparison to Transarterial Chemoembolisation With Cisplatin (TACE) in Patients With Liver Metastases From Uveal Melanoma. Provided by Prof. Dr. Ulrich Keilholz, Charité – University of medicine Berlin. EudraCT-Nummer: 2014-002439-32. NCT02936388.

Risk perception and optimism during the early stages of the COVID-19 pandemic - Questionnaire risk perception and optimism about COVID-19

- 05/01/2022 - 1 Formulário, 7 Grupos de itens, 151 Elementos de dados, 1 Idioma

Grupos de itens: Risk perception for COVID-19, Control questions for optimism, Adherence to protective measures, Mental health, General control questions, Other, Demographics

In this study, we assessed risk perception and optimism about COVID-19 in a multinational (UK, USA and Germany), longitudinal design during the early stages of the pandemic (16 March 2020; 1 April 2020; 20 May 2020). Our main findings are that (i) people showed a comparative optimism bias about getting infected and infecting others, but not for getting severe symptoms, (ii) this optimism bias did not change over time, (iii) optimism bias seemed to relate to perceived level of control over the action, (iv) risk perception was linked to publicly available information about the disorder, (v) people reported adhering closely to protective measures but these measures did not seem to be related to risk perception, and (vi) risk perception was related to questions about stress and anxiety. Kuper-Smith BJ, Doppelhofer LM, Oganian Y, Rosenblau G, Korn CW. 2021 Risk perception and optimism during the early stages of the COVID-19 pandemic. R. Soc. Open Sci. 8: 210904. https://doi.org/10.1098/rsos.210904

GSK Ofatumumab in Waldenstrom Macroglobulinaemia, NCT00811733 - Electronically transferred lab data

- 26/11/2021 - 1 Formulário, 4 Grupos de itens, 9 Elementos de dados, 1 Idioma

Grupos de itens: Administrative Data, Blood sample, Neuro Antibody panel, Prognostic factors

Study ID: 110921 Clinical Study ID: 110921 Study Title: A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00811733 Clinicaltrials.gov Link: https://clinicaltrials.gov/ct2/show/NCT00811733 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Ofatumumab Trade Name: N/A Study Indication: Waldenstrom Macroglobulinaemia The primary objective of this open-label, multi-center, Phase II study was to evaluate the safety and efficacy of Ofatumumab in subjects diagnosed with Waldenstrom Macroglobulinaemia. For the study, eligible subjects were enrolled to receive up to 3 cycles of treatment with Ofatumumab. The first cycle consisted of a single dose of 300 mg followed by 3 weekly doses of 1000 mg (Treatment Group A) or 4 weekly doses of 2000 mg (Treatment Group B) of Ofatumumab, with response assessment beginning at Week 12. Based on the Week 12-16 response, eligible subjects could receive up to 2 additional cycles of treatment. This form is for documentation of electronically transferred lab data and is used for screening, cycle 1 weeks 1-4 and observation, cycle 2 weeks 1-4 and observation and on a potential withdrawal visit, as well as any unscheduled lab data available.

GSK Ofatumumab in Waldenstrom Macroglobulinaemia, NCT00811733 - PK Blood Sample

- 26/11/2021 - 1 Formulário, 3 Grupos de itens, 9 Elementos de dados, 1 Idioma

Grupos de itens: Administrative Data, Dosing date and time, PK Blood Sample

Study ID: 110921 Clinical Study ID: 110921 Study Title: A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00811733 Clinicaltrials.gov Link: https://clinicaltrials.gov/ct2/show/NCT00811733 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Ofatumumab Trade Name: N/A Study Indication: Waldenstrom Macroglobulinaemia The primary objective of this open-label, multi-center, Phase II study was to evaluate the safety and efficacy of Ofatumumab in subjects diagnosed with Waldenstrom Macroglobulinaemia. For the study, eligible subjects were enrolled to receive up to 3 cycles of treatment with Ofatumumab. The first cycle consisted of a single dose of 300 mg followed by 3 weekly doses of 1000 mg (Treatment Group A) or 4 weekly doses of 2000 mg (Treatment Group B) of Ofatumumab, with response assessment beginning at Week 12. Based on the Week 12-16 response, eligible subjects could receive up to 2 additional cycles of treatment. Depending on which items, this form has to be filled out at the Cycle 1 week 1, 2, 3 and 4 visits, Cycle 2 week 1, 2, 3 and 4 visits, Cycle 1 and 2 observation visits and unscheduled visits.

Palavras-chave

Índice

Modelos de dados selecionados

Laboratory Visit 04 SirTac NCT02936388 - Laboratory Visit 04

Laboratory Before every SIRT- or TACE- Treatment SirTac NCT02936388 - Laboratory Before every SIRT- or TACE- Treatment

Laboratory Visit 07 SirTac NCT02936388 - Laboratory Visit 07

Laboratory Screening Day -7 to 0 SirTac NCT02936388 - Laboratory Screening Day -7 to 0

Laboratory Screening Day -7 to 0 SirTac NCT02936388 - Laboratory Screening Day -7 to 0

Laboratory End of Therapy SirTac NCT02936388 - Laboratory End of Therapy

Laboratory 12- Weeks Visits SirTac NCT02936388 - Laboratory 12- Weeks Visits

Iodine-131 Anti-B1 Antibody for Non Hodgkin’s Lymphomas NCT00996593 - Physical Examination, Laboratory Results Hematology/ Chemistry Follow- Up